Skip to content

Recording / Slides

Two recent landmark HIV Prevention Trials Network (HPTN) studies demonstrated the efficacy of long-acting, injectable cabotegravir (CAB) as PrEP against HIV. These studies showed that CAB for PrEP injected once every eight weeks was superior to daily oral tenofovir/emtricitabine (TDF/FTC) for PrEP among cisgender men and transgender women who have sex with men (HPTN 083) and cisgender women (HPTN 084). Both studies demonstrated that CAB for PrEP was well-tolerated, offering a new and important PrEP option for individuals at risk for HIV infection.

As regulatory approvals for CAB for PrEP move forward, Raphael J. Landovitz, MD, MSc, the HPTN 03 Protocol chair, will discuss findings from the randomized controlled trial and ongoing open-label extension phases of the studies, including some thoughts on opportunities and challenges of clinical implementation in this grand rounds.

This webinar is being presented by ICAP. Based at Columbia University with operations in more than 30 countries, ICAP is a leader in global public health, internationally known for tackling the world’s toughest health challenges—from HIV to tuberculosis, from malaria to maternal and child health, and the growing problem of non-communicable diseases, and most recently, the COVID-19 pandemic. Through innovative research, collaborative technical assistance, and a focus on strengthening health systems, ICAP helps to create better, more accessible, health services to reduce the burden of illness on people and communities.

Featured Resources